Background We investigated the effect of the 7-valent pneumococcal conjugate vaccine (PCV7)
programme in England on serotype-specific carriage and invasive disease to help …

OBJECTIVE: To inform national policy making on the use of the 13-valent pneumococcal
vaccine among risk groups we estimated the increased risk of invasive pneumococcal disease (…

Objectives To assess the burden of influenza by age and clinical status and use this to inform
evaluations of the age and risk-based influenza vaccination policy in the United Kingdom. …

Background/Aims In April 2010 the 7-valent pneumococcal conjugate vaccine (PCV7) was
replaced by the 13-valent PCV. We investigated pneumococcal carriage in children eligible …

Decisions on how to mitigate an evolving pandemic are technically challenging. We present
a real-time assessment of the effectiveness and cost-effectiveness of alternative influenza A/…

Background In many regions of the world, vaccine hesitancy has become an important
concern to public health. A key part of any effective solution to it is to gain an in-depth …

A live-attenuated vaccine against herpes zoster (HZ) has been approved for use, on the
basis of a large-scale clinical trial that suggests that the vaccine is safe and efficacious. This …

Background Differences in pathogenicity between pneumococcal serotypes are important
when assessing the potential benefit of different valency vaccines. We investigated the effect …

Background While the H1N1v influenza pandemic in 2009 was clinically mild, with a low
case-fatality rate, the overall disease burden measured in quality-adjusted life years (QALY) lost …

Objectives To update cost effectiveness estimates for the four dose (3+1) schedule of the
seven valent pneumococcal conjugated vaccine (PCV-7) in the Netherlands and to explore the …